CN Patent

CN107548394A — 调节激酶的化合物的固体形式

Assigned to First Three Co ltd · Expires 2018-01-05 · 8y expired

What this patent protects

制备和表征作用于受体蛋白激酶c‑Kit和/或c‑Fms和/或Flt3的化合物[5‑(5‑氯‑1H‑吡咯并[2,3‑b]吡啶‑3‑基甲基)‑吡啶‑2‑基]‑(6‑三氟甲基‑吡啶‑3‑基甲基)‑胺盐酸盐(化合物I)的固体形式和其游离碱。还提供使用所述固体形式的方法。

USPTO Abstract

制备和表征作用于受体蛋白激酶c‑Kit和/或c‑Fms和/或Flt3的化合物[5‑(5‑氯‑1H‑吡咯并[2,3‑b]吡啶‑3‑基甲基)‑吡啶‑2‑基]‑(6‑三氟甲基‑吡啶‑3‑基甲基)‑胺盐酸盐(化合物I)的固体形式和其游离碱。还提供使用所述固体形式的方法。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN107548394A
Jurisdiction: CN
Classification: —
Expires: 2018-01-05
Drug substance claim: No
Drug product claim: No
Assignee: First Three Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.